Board of Directors
Chairman & CEO
Ryuji Suzuki, Ph.D.
Ryuji Suzuki is a central figure among the founding members of the Company, and has over 30 years’ research experience in immunology. He has a work experience in the private sector, including Shionogi & Co., Ltd. and Takeda Pharmaceutical Company Limited, and he has a strong network of key opinion leaders (KOLs) in various research areas, as well as being familiar with academia and with pharmaceutical company research. He concurrently serves as the Research Head of the Department of Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital.close
Director & Senior Corporate Officer
Eiichi Yamaguchi, Ph.D.
Eiichi Yamaguchi has accumulated substantial business experience from over 30 years’ service at Shionogi & Co., Ltd., including roles involving MR, clinical development, business development, overseas business and liaison with parties outside the industry. He joined the Company in June 2019 in as a business development supervisor, and currently oversees the Company’s new projects as head of the Innovative Business Creation Department.close
President & COO
Masuo Ichikawa has extensive experience of business development, marketing and sales in Japanese biotech startup company and Abbott Japan, Co., Ltd. Since joining the Company in June 2015, he has been involved in a range of different roles at the Company including supervision of sales and business development, laboratory operations and research and development. He became Chief Operating Officer of the Company in April 2021.close
Director & Senior Corporate Officer
Tetsuya Maruyama joined SymBio Pharmaceuticals Limited, a listed bio-venture (JASDAQ Growth of Tokyo Stock Exchange) in the second year of its development after working at various internet-related and other companies. He has extensive experience of new stock market listings and fundraising for listed and unlisted companies, based on roles in finance/accounting and IR. He joined the Company in September 2016 and oversees its back-office operations.close
Tsuneaki Sakata, Ph.D.
Tsuneaki Sakata is one of the Company’s founding shareholders. He became an outside director of the Company in March 2018. After joining Shionogi & Co., Ltd. as a laboratory researcher, he held various positions in industry-government-academia, including senior fellow at Shionogi’s research lab, visiting professor at the Promotion Department for Research Administration & Collaboration, Tokushima University, specially appointed professor at Co-Creation Bureau, Osaka University, and specially appointed fellow at Japan Science and Technology Agency (JST), a national research and development agency. He has extensive experience in R&D and open innovation at pharmaceutical companies.close
Tadasu Shin-i, Ph.D.
Tadasu Shin-i is one of the Company’s founding shareholders. He became an outside director of the Company in March 2019. As the CEO of BITS Co., Ltd., a company that specializes in bioinformatics, he has a broad scientific background as well as expert knowledge of bioinformatics.close
Atsushi Usami, Ph.D.
Atsushi Usami joined the University of Tokyo Edge Capital Co., Ltd. (UTEC) in 2013 after having worked at Mitsubishi Research Institute, Inc. After the Company was established, he was appointed as outside director in November 2014. As a director and partner of the University of Tokyo Edge Capital Partners Co., Ltd., he is involved in investment in seed/early stage startup companies, primarily in the life sciences sector, as well as in their management.close
Masahiro Kanamaru, MBA
Masahiro Kanamaru joined Beyond Next Ventures Inc. in 2016 after having worked at Toshiba Corporation and DBJ Capital Co., Ltd. He became an outside director of the Company in March 2020. He has experience in investment and management of companies in the life sciences, electronics and AI sectors.close
Takeaki Furihata has over 30 years’ of experience in underwriting IPOs at New Japan Securities Co., Ltd. and Shinko Securities Co., Ltd. (both now Mizuho Securities Co., Ltd.) and Mizuho Securities Co., Ltd. He became a full-time auditor of the Company in April 2017. He concurrently serves as an outside director (Audit and Supervisory Committee Member) of FB CARE SERVICE CO., LTD.close
Toshiharu Ko worked at the Long-Term Credit Bank of Japan, Ltd. (currently Shinsei Bank, Limited) before working in audit operations at Deloitte Touche Tohmatsu LLC in 1999. He launched Ko Toshiharu Accounting Office in 2014, and became a Company external auditor in April 2017. He has extensive management experience through his involvement in start-ups and IPOs of venture businesses and other companies. He is a certified public accountant and certified tax accountant.close
Noriaki Sakamoto, MBA
Noriaki Sakamoto worked at the Ministry of Economy, Trade and Industry and McKinsey & Company before joining the University of Tokyo Edge Capital Co., Ltd. (UTEC) in 2014. After the establishment of the Company, he became an external auditor of the Company in November 2014. As a director and partner of the University of Tokyo Edge Capital Partners Co., Ltd., he is involved with investment and management of companies in various industries ranging from life sciences to IT and AI.close
Kazutaka Kitaura, Ph.D.
Kazutaka Kitaura is one of the founding members of the Company. He has wide experience of immunology research as a researcher at the Department of Clinical Immunology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, and at the National Institute of Infectious Diseases. Since the foundation of the Company, he has accumulated experience and a track record in various areas, such as development of analysis systems, establishment of reliability assurance systems and laboratory operations.close
Takaji Matsutani, Ph.D.
Takaji Matsutani is one of the founding members of the Company. He has accumulated an in-depth knowledge of immunology through research experience at Shionogi & Co., Ltd. and academic institutions, such as Tohoku University and the University of Miami. Since the foundation of the Company, he has been engaged in a wide range of joint R&D projects with academia and pharmaceutical companies.close